Interest in stenting for the treatment of symptomatic high-grade intracranial atherosclerosis may be rekindled after the results of a new trial showing lower rates of in-stent restenosis and stroke ...

Despite the impressive benefits obtained following the introduction of the drug-eluting stent, safety concerns have been raised over their long-term safety with particular regard to stent thrombosis.

Designed for Enhanced Deliverability and Flexibility to Treat Patients with Complex Coronary Artery Disease Built Upon the Proven Clinical Outcomes of Abbott's Cobalt Chromium Stent Technology, With a ...

LAS VEGAS and MARLBOROUGH, Mass., Oct. 6, 2021 /PRNewswire/ -- Today, Boston Scientific Corporation (NYSE: BSX) announced positive data for the Eluvia™ Drug-Eluting Vascular Stent System (Eluvia stent ...

For patients with symptomatic coronary artery disease, the best course of action often involves implanting a drug-eluting stent into the artery where a plaque buildup is blocking blood flow to the ...

COPD may increase cerebral microbleed risk Newer-generation drug-eluting stents reduce MI risk, target revascularization in women with coronary artery disease. Level 2: Mid-level evidence Drug-eluting ...

The continued success of drug-eluting stents relies heavily on little-known technologies. Parylene, for example, could have far-reaching applications. Lonny Wolgemuth Drug-eluting stents, although ...

The initial trials of drug-eluting stents (DESs) demonstrated marked reductions in restenosis and the need for repeat revascularization procedures, and resulted in the near instantaneous adoption of ...

Drug-eluting stents are an established treatment option for coronary artery disease, although they are not without their problems. The MAHOROBA ® stent attempts to harness the theoretical advantages ...

XIENCE Xpedition™ 48 Leverages Proven Design and Clinical Outcomes of the XIENCE Family of Drug Eluting Stents Has the Potential to Reduce Overall Procedural Costs Very Long Lesions Most Often Seen in ...

SORT OUT IV Data Presented at TCT in Washington DC Shows Remarkable Safety and Efficacy Measures with Both CYPHER Stent and Xience Stent BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Investigators reported ...

A research team has demonstrated that clopidogrel is more effective than aspirin as a long-term antiplatelet therapy in patients at high risk of recurrent cardiovascular events after coronary stent ...